CDH17 Antibodies

Structure of CDH17

CDH17 is a membrane glycoprotein with a molecular weight of approximately 90-100 kDa. Its size varies slightly among different species due to glycosylation modifications.

This protein is composed of approximately 832 amino acids. Its structure includes a signal peptide, an extracellular region containing multiple cadherin repeat sequences (responsible for mediating calcium-dependent homotypic cell adhesion), a transmembrane region, and an intracellular tail. CDH17 forms dimers through its extracellular domain, and its intracellular segment does not bind to classical connexins but participates in cell signal transduction through unique interactions. This protein plays a crucial role in maintaining the integrity of the intestinal epithelial barrier, and its abnormal expression is closely related to the occurrence and development of various digestive tract tumors.

Fig. 1 Schematic diagramme of Wnt/β-catenin pathway with CDH17-mediated regulation in cancer biology.¹

The core structural features of CDH17:

• Contains 7 extracellular cadherin repeat sequences, mediating calcium-dependent homophilic adhesion
• The transmembrane domain is anchored to the cell membrane, and the intracellular tail end independently conducts signals
• The extracellular domain forms parallel dimers, enhancing adhesion stability
• Unique catenin-independent signaling mechanism that regulates Wnt pathway activity

Functions of CDH17

The main function of CDH17 is to mediate calcium-dependent homotypic cell adhesion and maintain the integrity of intestinal epithelium. However, it is also involved in various pathological processes, including tumor occurrence and regulation of the Wnt signaling pathway.

Unlike other cadherins, the intracellular segment of CDH17 does not bind to the classical cadherins. Instead, it regulates downstream signals through a unique non-cadherin-dependent mechanism, playing a crucial role in tumor development.

Applications of CDH17 and CDH17 Antibody in Literature

1. Tha Shrestha, Bipusha, et al. "The role of cadherin 17 (CDH17) in cancer progression via Wnt/β-catenin signalling pathway: a systematic review and meta-analysis." International Journal of Molecular Sciences 26.20 (2025): 9838. https://doi.org/10.3390/ijms26209838

The review reveals that CDH17 drives the Wnt/β-catenin signaling pathway in multiple cancer types. Inhibiting CDH17 can reduce downstream activity and decrease tumor proliferation and metastasis. The inhibition rate of tumor growth in vivo reaches 80% - 95%, making it a potential broad-spectrum anti-cancer target.

2. Jacobsen, Frank, et al. "Cadherin-17 (CDH17) expression in human cancer: A tissue microarray study on 18,131 tumors." Pathology-Research and Practice 256 (2024): 155175. https://doi.org/10.1016/j.prp.2024.155175

Through the analysis of nearly 15,000 samples, the study confirmed that CDH17 is highly expressed in normal tissues such as intestinal epithelium and various digestive tract tumors. This finding is helpful in differentiating metastatic digestive tract tumors from primary lung adenocarcinoma and makes it a potential diagnostic marker.

3. Zheng, Liuhai, et al. "CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers." Acta Pharmaceutica Sinica B 15.5 (2025): 2559-2574. https://doi.org/10.1016/j.apsb.2025.03.039

The research and development of CAR-NK cells targeting CDH17 can effectively eliminate digestive tract tumors. Combined with the CD47 inhibitor CV1, it can synergistically enhance the anti-tumor effect, providing a new strategy for treatment.

4. Ng, Lui, et al. "Tissue Cadherin 17 (CDH17): An Important Prognostic Determinant of Colorectal Cancer Using Digital Image Analysis." Cancer Reports 7.12 (2024): e70069. https://doi.org/10.1002/cnr2.70069

Studies have confirmed that CDH17 is highly expressed in colorectal cancer tissues and is significantly associated with tumor stage progression, metastasis, and poor prognosis. It is an independent prognostic marker for evaluating patient survival and recurrence.

5. Ma, Jingbo, et al. "CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin." Biomaterials research 26.1 (2022): 64. https://doi.org/10.1186/s40824-022-00312-3

The study has obtained highly specific nanobodies targeting CDH17, which can enable imaging of gastric cancer and toxin delivery. The immunotoxin significantly suppressed tumor growth and prolonged survival in animal models, demonstrating its potential for clinical application.

Creative Biolabs: CDH17 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CDH17 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom CDH17 Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CDH17 antibodies, custom preparations, or technical support, contact us at email.